Misplaced Pages

Filaminast

Clinical data
ATC code	None
Legal status
Legal status	Development terminated
Identifiers
IUPAC name carbamate
CAS Number	141184-34-1
PubChem CID	9578243
DrugBank	DB02660
ChemSpider	7852607
UNII	CDD69JC61J
KEGG	D04185
CompTox Dashboard (EPA)	DTXSID80869910
Chemical and physical data
Formula	C15H20N2O4
Molar mass	292.335 g·mol
3D model (JSmol)	Interactive image
SMILES CC(=NOC(=O)N)C1=CC(=C(C=C1)OC)OC2CCCC2

Filaminast (code name WAY-PDA 641) was a drug candidate developed by Wyeth-Ayerst. It is a phosphodiesterase 4 inhibitor (PDE4 inhibitor) and an analog of rolipram, which served as a prototype molecule for several development efforts. It was discontinued after a Phase II trial showed that its therapeutic window was too narrow; it could not be dosed high enough without causing significant side effects (nausea and vomiting), which was a problem with the rolipram class of molecules.

See also

• Piclamilast
• Roflumilast

References

1. "Filaminist entry". Pubchem.
2. Halpin DM (2008). "ABCD of the phosphodiesterase family: interaction and differential activity in COPD". International Journal of Chronic Obstructive Pulmonary Disease. 3 (4): 543–61. doi:10.2147/COPD.S1761. PMC 2650605. PMID 19281073.
3. Giembycz MA (October 2008). "Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?". British Journal of Pharmacology. 155 (3): 288–90. doi:10.1038/bjp.2008.297. PMC 2567889. PMID 18660832.
4. ^ McKenna JM, Muller GW (5 December 2006). "Medicinal Chemistry of PDE4 Inhibitors. Chapter 33". In Beavo JA, Francis SH, Houslay MD (eds.). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press. ISBN 978-1-4200-2084-7.

• Drugs not assigned an ATC code
• Abandoned drugs
• Carbamates
• PDE4 inhibitors
• Phenol ethers
• Cyclopentyl compounds